Information

TRUNCATE-TB assesses multiple experimental treatment arms that combine new drugs or optimized doses of existing anti-tuberculosis medicines, compared against the standard six-month regimen. The primary endpoint is the proportion of patients with unsatisfactory outcomes at two years after randomization. The study plans to enroll up to 900 adult patients with newly diagnosed DS-TB across all participating sites.

• University College London (UCL)

• National University Hospital (Singapore)

• RSUP Persahabatan

• Hasan Sadikin Hospital (Bandung)

• Saiful Anwar Hospital (Malang)

• Soetomo General Hospital (Surabaya)

• Wahidin Sudirohusodo Hospital (Makassar)

Type of Study

Stakeholders Involved

Tuberculosis Clinical Trial

Background

The current standard treatment for drug-sensitive tuberculosis requires a six-month multidrug regimen, which, despite high cure rates, is associated with challenges such as poor adherence, treatment fatigue, and increased risk of unfavorable outcomes. Shorter, more effective treatment strategies could improve patient adherence, reduce healthcare burden, and lower the risk of drug resistance. TRUNCATE-TB explores whether intensified short-course regimens can safely and effectively replace the conventional approach.